Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE: HPG1860 in Nonalcoholic Steatohepatitis
NCT05338034Phase 2Completed
- Sponsor
- Hepagene Therapeutics
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hpg1860 in Nonalcoholic steatohepatitis (NASH), sponsored by Hepagene Therapeutics. Started Nov 2021; status: completed.
02
Drugs
hpg1860
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05338034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338034.